Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_assertion type Assertion NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_head.
- NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_assertion description "[BRAF genotype is correlated with PFS and OS in KRAS wild type mCRC patients, which is independent of cetuximab treatment. PIK3CA mutation, loss of PTEN expression, EGFR GCN and HER2 GCN have no predictive value for response to treatment with cetuximab, ne]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_provenance.
- NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_assertion evidence source_evidence_literature NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_provenance.
- NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_assertion SIO_000772 20413299 NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_provenance.
- NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_assertion wasDerivedFrom gad-20150221 NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_provenance.
- NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_assertion wasGeneratedBy ECO_0000203 NP173402.RAbTJKUEBein4UqCWuazEnhbTHxEgslHpyDbXfeS43BvQ130_provenance.